14.12.2018
- US biopharma AVEO Oncology is collaborating with Anglo-Swedish drug major AstraZeneca on a combined treatment for liver cancer. The partners will evaluate the safety and efficacy...
14.11.2018
- Anglo-Swedish drugmaker AstraZeneca has sold US right for its Synagis infant respiratory drug to Swedish Orphan Biovitrum (Sobi) for an upfront sum of $1.5 billion. The payment...
09.11.2018
- AstraZeneca, the British-Swedish pharma major, is selling rights outside the US for the respiratory drugs Alvesco, Omnaris, and Zetonna. Buyer is Zug, Switzerland-based Covis...
08.11.2018
- AstraZeneca is selling certain rights to Nexium and Vimovo to German drugmaker Grünenthal, having decided the drugs falls outside its main therapy areas of oncology, cardiovascular...
10.08.2018
- AstraZeneca has agreed to pay $110 million to settle a pair of whistleblower lawsuits in the US that accused it of fraudulently marketing Seroquel and Crestor to Texas Medicaid...
31.07.2018
- Anglo-Swedish drugmaker AstraZeneca has agreed to sell commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (fixed-dose combination of candesartan cilexetil and...
04.03.2018
- MedImmune, the biologics R&D arm of Anglo-Swedish drugmaker AstraZeneca, is spinning out six molecules from its early-stage inflammation and autoimmunity programs into new...
01.03.2018
- The US Food and Drug Administration (FDA) has approved AstraZeneca and MedImmune’s immunotherapy Imfinzi (durvalumab) to treat patients with a certain form of lung cancer. Imfinzi...
